![Tracey Martin](https://profiles-cardiff.imgix.net/attachments/10621?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Tracey Martin
(hi/ei)
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Tracey Martin
Uwch Ddarlithydd mewn Bioleg Cell a Tumour, Cyfarwyddwr Ymchwil Ôl-raddedig
Trosolwg
Ar ôl PhD mewn Bioleg Moleciwlaidd ym Mhrifysgol Caerdydd, dechreuais yrfa ôl-ddoethurol yng Ngholeg Meddygaeth Prifysgol Cymru, gan ymchwilio i rôl Ffactor Twf Hepatocyte (HGF) ar endothelia. Arweiniodd hyn at y cyfle i archwilio HGF a'i wrthwynebydd NK4 mewn canser. Ers 1998, rwyf wedi bod yn ymwneud ag ymchwilio i rôl cyffyrdd tynn mewn canser (yn ystod metastasis) ac mewn endothelia (yn ystod angiogenesis). Mae fy niddordebau ymchwil yn cynnwys ymchwilio i sut y gellir modiwleiddio cyffyrdd tynn i reoli dissociation a goresgyniad celloedd canser, ynghyd â diddordeb parhaus mewn ffactorau angiogenig a'u rôl mewn metastasis. Mae gen i ddiddordeb penodol mewn metastasis yr ymennydd ac mae rôl cyffyrdd tynn yn ennill y rhwystr ymennydd gwaed. Mae fy nhîm yn gweithredu ar y mecanweithiau sy'n gysylltiedig â thargedau therapiwtig posibl/therapïau newydd.
Rolau eraill:
- Arweinydd Astudiaethau Ymchwil Ôl-raddedig yr Ysgol Meddygaeth
- Cyfarwyddwr Rhaglenni Ysgolheigion Gaeaf a Haf Rhyngwladol yr Ysgol Feddygaeth
- Yr Adran Canser a Geneteg Arweinydd Pobl a Diwylliant
- Hyrwyddwr Lles yr Ysgol Meddygaeth
- Cyd-gadeirydd Rhwydwaith Staff Anabledd y Brifysgol
Cyhoeddiad
2026
- Tian, Q. et al. 2026. Iteratively calibrated s11 thermometry for microsecond-scale intra-pulse heating in 96-well plates. Presented at: 2026 IEEE MTT-S Radio Frequency Systems and Applications Symposium (IMS RFSA) Boston, MA, USA 7-12 June 2026. 2026 IEEE MTT-S Radio Frequency Systems and Applications Symposium (IMS RFSA). IEEE. , pp.430-433. (10.1109/imsrfsa70221.2026.11624232)
- Xu, Z. et al., 2026. SLC27, Solute Carrier 27 family, a long-chain fatty acid membrane transporters, in human cancers. Frontiers in Cell and Developmental Biology 14 1839021. (10.3389/fcell.2026.1839021)
- Sun, Z. , Martin, T. A. and Jiang, W. G. 2026. Exploring nonviral nanocarriers as RNA delivery platforms for the treatment of breast cancer. Chemical Engineering Journal 538 176496. (10.1016/j.cej.2026.176496)
- Jiao, J. , Martin, T. A. and Jiang, W. 2026. Beyond barrier function: Tight junctions as dynamic signaling hubs orchestrating tumor plasticity, microenvironment remodeling, and metastatic evolution. Immune Discovery 2 (2) 10004. (10.70322/immune.2026.10004)
- Yao, H. et al., 2026. Molecular mechanisms and therapeutic targeting implications of ER/mTOR signaling axis-driven tumor progression in aggressive meningiomas. Translational Oncology 66 102723. (10.1016/j.tranon.2026.102723)
- Xiang, H. et al. 2026. SRS123 - Clinical relevance of MarvelD2 as a prognostic biomarker in clinical breast cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.119. (10.1093/bjs/znag018.119)
- Chen, D. Y. et al., 2026. SRS387 - MLN64/StarD3 and StarD3NL in pancreatic cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.343. (10.1093/bjs/znag018.343)
- Li, A. X. et al. 2026. SRS126 - MLN64 and StarD3NL highly correlated with the autophagy marker SQSTM1 and BECN1 in breast cancer, and indicate prognostic and therapeutic potential [Abstract]. British Journal of Surgery 113 (S2) znag018.122. (10.1093/bjs/znag018.122)
- O’Neill, N. et al. 2026. SRS359 - A novel association between disialoganglioside (GD2), GD2 synthesising enzymes and the Angiomotin family in breast cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.318. (10.1093/bjs/znag018.318)
- Sun, Z. , Jiang, W. and Martin, T. 2026. SRS127 - Afadin (AFDN) and the nectin protein complex in the development of metastasis of breast cancers [Abstravt]. British Journal of Surgery 113 (S2) znag018.123. (10.1093/bjs/znag018.123)
- Xiang, H. et al. 2026. SRS133 - Nucleolin (NCL) in clinical breast cancer, the prognostic and therapeutic implications [Abstract]. British Journal of Surgery 113 (S2) znag018.129. (10.1093/bjs/znag018.129)
- Cong, B. et al., 2026. MLN51 (Metastatic Lymph Node Gene 51)/CASC3 (Cancer Susceptibility Candidate Gene 3), A putative tumour suppressor in breast cancer, the clinical and therapeutic connections. Breast Cancer: Targets and Therapy 18 (2026), pp.1-17. (10.2147/BCTT.S565199)
- Cong, B. et al., 2026. MLN51 (metastatic lymph node gene 51)/CASC3 (cancer susceptibility candidate gene 3), a putative tumour suppressor in breast cancer, the clinical and therapeutic connections. Breast Cancer: Targets and Therapy 18 (10.2147/bctt.s565199)
- Li, A. X. et al. 2026. Targeting the MLN64/STARD3-cholesterol axis disrupts tight junction remodelling and attenuates gastric cancer aggressiveness. Frontiers in Oncology (10.3389/fonc.2026.1913732)
2025
- Zhu, K. et al., 2025. Tumor exosomal miR-221-3p induces glycolysis through the LIFR/GLUT1 pathway to destroy the cerebral vascular endothelial cell barrier and promote breast cancer brain metastasis. Journal of Translational Medicine 23 (1) 1333. (10.1186/s12967-025-07372-8)
- Wazir, U. et al., 2025. CD84 as a prognostic biomarker and therapeutic target in breast cancer: Interconnections with PDL1, CD74, and immune tolerance mechanisms. Cancer Genomics & Proteomics 22 (4), pp.557-563. (10.21873/cgp.20521)
- Ji, W. et al. 2025. Tight junctional protein family, Claudins in cancer and cancer metastasis. Frontiers in Oncology 15 1596460. (10.3389/fonc.2025.1596460)
- Ji, W. et al. 2025. Knockdown of claudin-8 (CLDN8) indicates a link between breast cancer cell sensitivity to chemotherapeutics and reveals a potential use of CLDN8 as a molecular diagnostic and target for therapy. International Journal of Molecular Sciences 26 (11) 5412. (10.3390/ijms26115412)
- Yu, R. Y. , Jiang, W. G. and Martin, T. A. 2025. The WASP/WAVE protein family in breast cancer and their role in the metastatic cascade. Cancer Genomics & Proteomics 22 (2), pp.166-187. (10.21873/cgp.20495)
- Tong, J. et al. 2025. DRIM modulates Src activation and regulates angiogenic functions in vascular endothelial cells. Cell Biology International 49 (3), pp.277-287. (10.1002/cbin.12265)
- O’Neill, N. S. et al. 2025. Correlation of GD2 biosynthesis enzymes with cancer stem cell markers in human breast cancer. Cancer Genomics & Proteomics 22 (2), pp.231-246. (10.21873/cgp.20498)
2024
- Zeng, J. et al. 2024. EPLIN, a prospective oncogenic molecule with contribution to growth, migration and drug resistance in pancreatic cancer. Scientific Reports 14 (1) 30850. (10.1038/s41598-024-81485-w)
- Zhu, K. et al., 2024. Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway. Journal of Neuro-Oncology 170 , pp.331-345. (10.1007/s11060-024-04797-x)
- Li, A. X. et al. 2024. Metastatic Lymph Node 64 (MLN64) expression in gastric cancer, the clinical and molecular implications in drug resistance. Cancer Genomics & Proteomics 21 (1), pp.30-40. (10.21873/cgp.20427)
- Li, A. X. et al., 2024. Cellular impacts of striatins and the STRIPAK complex and their roles in the development and metastasis in clinical cancers. Cancers 16 (1) 76. (10.3390/cancers16010076)
2023
- Zhuang, X. et al., 2023. Expression of Claudin-9 (CLDN9) in breast cancer, the clinical significance in connection with its subcoat anchorage proteins ZO-1 and ZO-3 and impact on drug resistance. Biomedicines 11 (12) 3136. (10.3390/biomedicines11123136)
- Zhuang, X. et al. 2023. Claudin-10 in the blood brain barrier function of cerebral endothelial cells and transendothelial invasion of breast cancer cells. Anticancer Research 43 (9), pp.3923-3934. (10.21873/anticanres.16580)
- Frugtniet, B. A. et al. 2023. nWASP inhibition increases wound healing via TrKb/PLCγ signalling. Biomolecules 13 (2) 379. (10.3390/biom13020379)
- Li, A. X. et al. 2023. Striatins and the STRIPAK complex partners in the clinical outcome of patients with breast cancer and responses to drug treatment. Chinese Journal of Cancer Research 35 , pp.365-385. (10.21147/j.issn.1000-9604.2023.04.04)
2022
- Sui, L. et al. 2022. Death associated protein-3 (DAP3) and DAP3 binding cell death enhancer-1 (DELE1) in human colorectal cancer, and their impacts on clinical outcome and chemoresistance. International Journal of Oncology 62 (1) 7. (10.3892/ijo.2022.5455)
- Gao, H. et al., 2022. P-211 Claudin-16, its clinical and prognostic value in colorectal cancer. Annals of Oncology 33 , pp.S324-S324. (10.1016/j.annonc.2022.04.301)
- Sui, L. et al. 2022. P-282 Impact of death-associated protein-3 (DAP3) and DAP3 binding cell death enhancer 1 (DELE1) on drug sensitivity in colorectal cancer cells. Annals of Oncology 33 , pp.S347. (10.1016/j.annonc.2022.04.371)
- Telford, E. A. et al. 2022. Hepatitis A virus cellular receptor 1 (HAVcr-1) initiates prostate cancer progression in human cells via hepatocyte growth factor (HGF)-induced changes in junctional integrity. Biomolecules 12 (2) 338. (10.3390/biom12020338)
2021
- Xin, L. et al., 2021. SIKs suppress tumor function and regulate drug resistance in breast cancer. American Journal of Cancer Research 11 (7), pp.3537-3557.
- Martin, T. A. et al. 2021. NUPR1 and its potential role in cancer and pathological conditions (Review). International Journal of Oncology 58 (5) 21. (10.3892/ijo.2021.5201)
- Liu, C. et al. 2021. SIPA1 Is a modulator of HGF/MET induced tumour metastasis via the regulation of tight junction-based cell to cell barrier function. Cancers 13 (7) 1747. (10.3390/cancers13071747)
- Gong, W. et al., 2021. Location, function and role of stromal cell-derived factors and possible implications in cancer. International Journal of Molecular Medicine 47 (2), pp.435-443. (10.3892/ijmm.2020.4811)
2020
- Gong, W. et al., 2020. Influence of anaesthetics on the production of cancer cell motogens, stromal cell-derived factor-1 and hepatocyte growth factor by fibroblasts. Oncology Letters 21 (2) 140. (10.3892/ol.2020.12401)
- Liu, C. et al. 2020. The role of SIPA1 in the development of cancer and metastases (Review). Molecular and Clinical Oncology 13 (4) 32. (10.3892/mco.2020.2102)
- Cong, Y. et al., 2020. Tim-3 promotes cell aggressiveness and paclitaxel resistance through the NF-κB /STAT3 signalling pathway in breast cancer cells. Chinese Journal of Cancer Research 32 (5), pp.564-579. (10.21147/j.issn.1000-9604.2020.05.02)
- Wazir, U. et al., 2020. Stratification using hTERT and stem cell markers confers a good prognosis in invasive breast cancer. Cancer Genomics and Proteomics 17 (2), pp.169-174. (10.21873/cgp.20177)
- Zhao, Z. et al. 2020. Abstract P2-07-01: Kidins220 (kinase D interacting substrate 220) has a connection with neutrotrophic related factors, BDNF and NGF, in human breast cancer. Presented at: San Antonio Breast Cancer Symposium San Antonio, TX, United States 10-14 December 2019. Vol. 80.Vol. 4, Sup. , pp.P2-07-01. (10.1158/1538-7445.SABCS19-P2-07-01)
- Zhao, Z. et al. 2020. Abstract P3-01-18: Kinase D interacting substrate 220 (Kidins220) and disease progression of breast cancer, the role of heat shock protein90 (HSP90). Presented at: San Antonio Breast Cancer Symposium San Antonio, TX, United States 10-14 December 2019. Vol. 80.Vol. 4, Sup. American Association for Cancer Research. , pp.P3-01-18. (10.1158/1538-7445.SABCS19-P3-01-18)
2019
- Xu, Y. et al., 2019. BDNF activates TrkB/PLCγ1 signaling pathway to promote proliferation and invasion of ovarian cancer cells through inhibition of apoptosis. European Review for Medical and Pharmacological Sciences 23 (12), pp.5093-5100. (10.26355/eurrev_201906_18173)
- Wazir, U. et al., 2019. Correlation of TERT and stem cell markers in the context of human breast cancer. Cancer Genomics and Proteomics 16 (2), pp.121-127. (10.21873/cgp.20117)
2018
- Jia, J. et al., 2018. Fibroblast activation protein-α promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways. International Journal of Molecular Medicine 41 (1), pp.275-283. (10.3892/ijmm.2017.3224)
2017
- Xin, L. et al. 2017. The era of multigene panels comes? The clinical utility of Oncotype DX and MammaPrint. World Journal of Oncology 8 (2), pp.34-40. (10.14740/wjon1019w)
- Zhao, H. et al., 2017. The effect of aurora kinase inhibitor on adhesion and migration in human breast cancer cells and clinical implications. World Journal of Oncology 8 (5), pp.151-161. (10.14740/wjon1062w)
- Ismail, A. F. et al., 2017. PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells. Biochemical Journal 474 (8), pp.1333-1346. (10.1042/BCJ20160875)
- Frugtniet, B. A. et al. 2017. Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion. BMC Cancer 17 (1) 224. (10.1186/s12885-017-3219-3)
- Yang, X. et al., 2017. A novel NHERF1 mutation in human breast cancer and effects on malignant progression. Anticancer Research 37 (1), pp.67-73. (10.21873/anticanres.11290)
- Gu, Y. et al., 2017. NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway. Oncotarget 8 (5), pp.7753-7765. (10.18632/oncotarget.13949)
- Telford, E. , Jiang, W. G. and Martin, T. A. 2017. HAVcR-1 involvement in cancer progression. Histology and Histopathology 32 , pp.121-128. (10.14670/HH-11-817)
2016
- Liu, R. et al., 2016. Epithelial protein lost in neoplasm-α (EPLIN-α) is a potential prognostic marker for the progression of epithelial ovarian cancer. International Journal of Oncology 48 (6), pp.2488-2496. (10.3892/ijo.2016.3462)
- Zhao, H. et al. 2016. The role of JAM-B in cancer and cancer metastasis (Review). Oncology Reports 36 , pp.3-9. (10.3892/or.2016.4773)
- Martin, T. A. et al. 2016. Metastasis to bone in human cancer is associated with loss of occludin expression. Anticancer Research 36 (3), pp.1287-1294.
- Yang, X. et al., 2016. The impact of TIMM17A on aggressiveness of human breast cancer cells. Anticancer Research 36 (3), pp.1237-1241.
- Zhao, H. et al. 2016. The clinical implications of RSK1-3 in human breast cancer. Anticancer Research 36 (3), pp.1267-1274.
- Zhao, H. et al. 2016. Effect of junctional adhesion molecule-2 expression on cell growth, invasion and migration in human colorectal cancer. International Journal of Oncology 48 (3), pp.929-936. (10.3892/ijo.2016.3340)
- Jia, W. et al., 2016. Expression of the Epithelial-Mesenchymal-Transition (EMT) markers, Twist, Slug, Snail, E- and N-cadherins and the association with clinical and pathological features of human pituitary adenomas [Abstract]. European Journal of Cancer 51 (S3), pp.S592-S593. 2925. (10.1016/S0959-8049(15)30055-1)
2015
- Liu, R. et al., 2015. Metastasis suppressor 1 expression in human ovarian cancer: the impact on cellular migration and metastasis. International Journal of Oncology 47 (4), pp.1429-1439. (10.3892/ijo.2015.3121)
- Tan, Y. et al., 2015. Interleukin-24 (IL-24) expression and biological impact on HECV endothelial cells.. Cancer Genomics and Proteomics 12 (5), pp.243-250.
- Owen, S. et al., 2015. An investigation of Amphiphysin II transcript expression in pituitary adenomas [Abstract]. European Journal of Cancer 51 (S3), pp.S580-S580. 2806. (10.1016/S0959-8049(15)30053-8)
- Owen, S. et al., 2015. The prostate Transglutaminase, TGase-4, is potentially linked to the junctional proteins at tight junctions of prostate tissues and prostate cancer cells [Abstract]. European Journal of Cancer 51 (S3), pp.S481. 2516. (10.1016/S0959-8049(15)30048-4)
- Jiang, W. G. et al. 2015. YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells. Journal of Translational Medicine 13 280. (10.1186/s12967-015-0639-1)
- Ali, A. Y. et al. 2015. Anti-metastatic and cytotoxic properties of frankincense and scented myrrh. Anticancer Research 35 (7), pp.4310-4311.
- Fang, X. , Jiang, W. G. and Martin, T. A. 2015. The role of claudin-5 in the cell-cell adhesion of human keratinocytes. Anticancer Research 35 (7), pp.4367.
- Frugtniet, B. , Jiang, W. G. and Martin, T. A. 2015. Investigating the effect of NWASP (Neural Wiskott-Aldrich Syndrome Protein) inhibitors on human lung cancer cell behaviour. Anticancer Research 35 (7), pp.4348-4349.
- Jia, W. et al., 2015. Association of mta-1 expression in pituitary tumours with bone invasion. Anticancer Research 35 (7), pp.4360.
- Liu, R. et al., 2015. Metastasis suppressor 1 (MTSS1) expression in human ovarian cancer; the impact on cellular migration and metastasis [Abstract]. Anticancer Research 35 (7), pp.4342-4342.
- Martin, T. A. et al. 2015. Comparison of blood brain barrier endothelia reveals a differential expression of tight junction proteins [Abstract]. Anticancer Research 35 (7), pp.4357-4358.
- Martin, T. A. , Telford, E. and Jiang, W. G. 2015. HAVCR1 is a potential prognostic factor in human breast cancer. Anticancer Research 35 (7), pp.4327.
- Martin, T. A. and Tiang, W. G. 2015. The blood brain barrier and the prevention of metastatic disease. Anticancer Research 35 (7), pp.4298-4299.
- Jia, W. et al., 2015. Expression of metastasis-associated gene-1 is associated with bone invasion and tumor stage in human pituitary adenomas. Cancer Genomics and Proteomics 12 (3), pp.113-118.
- Frugtniet, B. , Jiang, W. G. and Martin, T. A. 2015. Role of the WASP and WAVE family proteins in breast cancer invasion and metastasis. Breast Cancer: Targets and Therapy 2015 (7), pp.99-109. (10.2147/BCTT.S59006)
- Jia, W. et al., 2015. Epithelial-mesenchymal transition (EMT) markers in human pituitary adenomas indicate a clinical course. Anticancer Research 35 (5), pp.2635-2643.
- Men, W. et al., 2015. Expression of claudins in human clear cell renal cell carcinoma. Cancer Genomics and Proteomics 12 (1), pp.1-8.
2014
- Martin, T. A. 2014. The role of tight junctions in cancer metastasis. Seminars in Cell and Developmental Biology 36 , pp.224-231. (10.1016/j.semcdb.2014.09.008)
- Martin, T. A. et al. 2014. Brain-derived neurotrophic factor (bdnf) is a novel therapeutic agent in human wound healing [Abstract]. Wound Repair and Regeneration 22 (5), pp.A91. (10.1111/wrr.12218)
- Ye, L. et al. 2014. Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumour-related angiogenesis. International Journal of Oncology 45 (4), pp.1565-1573. (10.3892/ijo.2014.2533)
- Martin, T. A. , Mason, M. D. and Jiang, W. G. 2014. HGF and the regulation of tight junctions in human prostate cancer cells. Oncology Reports 32 (1), pp.213-224. (10.3892/or.2014.3219)
- Jia, W. et al., 2014. The role of claudin-5 in blood-brain barrier ( BBB) and brain metastases (Review). Molecular Medicine Reports 9 (3), pp.779-785. (10.3892/mmr.2013.1875)
- Sun, T. T. et al., 2014. Disrupted interaction between CFTR and AF-6/afadin aggravates malignant phenotypes of colon cancer. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1843 (3), pp.618-628. (10.1016/j.bbamcr.2013.12.013)
- Feng, X. et al., 2014. Regulation and involvement in cancer and pathological conditions of MAGI1, a tight junction protein. Anticancer Research 34 (7), pp.3251-3256.
- Frugtniet, B. et al. 2014. nWASP (neural Wiskott-Aldrich syndrome protein) is a novel therapeutic target in human wound healing [Conference Abstract]. Wound Repair and Regeneration 22 (5), pp.A80-A80. (10.1111/wrr.12218)
- Jia, J. et al., 2014. FAP-alpha (Fibroblast activation protein-alpha) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biology 15 16. (10.1186/1471-2121-15-16)
- Lane, J. et al. 2014. Structure and role of WASP and WAVE in Rho GTPase signalling in cancer. Cancer Genomics and Proteomics 11 (3), pp.155-165.
- Martin, T. A. and Jiang, W. G. 2014. Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma. Oncology Reports 31 (1), pp.262-272. (10.3892/or.2013.2813)
2013
- Martin, T. A. et al. 2013. The expression of the Nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis. PLoS ONE 8 (12) e82696. (10.1371/journal.pone.0082696)
- Martin, T. A. and Jiang, W. G. 2013. Regulation of barrier function in human breast cancer can be controlled by the ROCK signalling pathway via interaction with SIPA-1 [Abstract]. European Journal of Cancer 49 , pp.S132-S132.
- Martin, T. A. et al. 2013. Claudin-20 promotes an aggressive phenotype in human breast cancer cells. Tissue Barriers 1 (3) e26518. (10.4161/tisb.26518)
- Martin, T. A. , Mason, M. D. and Jiang, W. G. 2013. HGF and the regulation of tight junctions in human prostate cancer cells [Abstract]. European Journal of Cancer 49 , pp.S132-S132.
- Martin, T. A. et al. 2013. Cancer invasion and metastasis: molecular and cellular perspective. In: Jandial, R. ed. Metastatic Cancer Clinical and Biological Perspectives. Austin, TX: Landes Bioscience. , pp.135-168.
- Wang, Y. , Martin, T. A. and Jiang, W. G. 2013. HAVcR-1 expression in human colorectal cancer and its effects on colorectal cancer cells in vitro.. Anticancer Research 33 (1), pp.207-214.
- Yang, X. , Martin, T. A. and Jiang, W. G. 2013. Biological influence of brain-derived neurotrophic factor (BDNF) on colon cancer cells. Experimental and Therapeutic Medicine 6 (6), pp.1475-1481. (10.3892/etm.2013.1330)
- Ye, L. et al. 2013. Psoriasin (S100A7) is a positive regulator of survival and invasion of prostate cancer cells. Urologic Oncology: Seminars and Original Investigations 31 (8), pp.1576-1583. (10.1016/j.urolonc.2012.05.006)
2012
- Escudero-Esparza, A. , Jiang, W. G. and Martin, T. A. 2012. Claudin-5 is involved in breast cancer cell motility through the N-WASP and ROCK signalling pathways. Journal of Experimental & Clinical Cancer Research 31 (1), pp.43-60. (10.1186/1756-9966-31-43)
- Ji, K. et al. 2012. Expression of signal-induced proliferation-associated gene 1 (SIPA1), a rapGTPase-activating protein, is increased in colorectal cancer and has diverse effects on functions of colorectal cancer cells. Cancer Genomics and Proteomics 9 (5), pp.321-327.
- Li, X. , Martin, T. A. and Jiang, W. G. 2012. COM-1/p8 acts as a tumour growth enhancer in colorectal cancer cell lines. Anticancer Research 32 (4), pp.1229-1237.
- Martin, T. A. et al. 2012. The clinical and biological implications of N-WASP expression in human colorectal cancer. Translational Gastrointestinal Cancer 1 (1), pp.10-20.
- Yang, X. , Martin, T. A. and Jiang, W. G. 2012. Biological influence of brain-derived neurotrophic factor on breast cancer cells. International Journal of Oncology 41 (4), pp.1541-1546. (10.3892/ijo.2012.1581)
2011
- Martin, T. A. et al. 2011. HAVcR-1 reduces the integrity of human endothelial tight junctions. Anticancer Research 31 (2), pp.467-473.
- Awsare, N. S. et al. 2011. Claudin-11 decreases the invasiveness of bladder cancer cells. Oncology Reports 25 (6), pp.1503-1509. (10.3892/or.2011.1244)
- Cheng, S. et al., 2011. Putative breast tumor suppressor TACC2 suppresses the aggressiveness of breast cancer cells through a PLCγ pathway. Current Signal Transduction Therapy 6 (1), pp.55-64. (10.2174/157436211794109361)
- Escudero-Esparza, A. , Jiang, W. G. and Martin, T. A. 2011. Claudin-5 participates in the regulation of endothelial cell motility. Molecular and Cellular Biochemistry 362 (1-2), pp.71-85. (10.1007/s11010-011-1129-2)
- Escudero-Esparza, A. , Jiang, W. G. and Martin, T. A. 2011. The Claudin family and its role in cancer and metastasis. Frontiers in Bioscience 16 (3), pp.1069-1083. (10.2741/3736)
- Lane, J. , Martin, T. A. and Jiang, W. G. 2011. HGF and rhoGTPases in cancer cell motility. Current Signal Transduction Therapy 6 (2), pp.173-179. (10.2174/157436211795660052)
- Martin, T. A. , Mason, M. D. and Jiang, W. G. 2011. Hepatocyte growth factor signalling in cancer metastasis. Current Signal Transduction Therapy 6 (2), pp.180-190. (10.2174/157436211795659991)
- Martin, T. A. , Mason, M. D. and Jiang, W. G. 2011. Tight junctions in cancer metastasis. Frontiers in Bioscience 16 (3), pp.898-936. (10.2741/3726)
- Minhas, U. et al. 2011. Pattern of expression of CCN family members Cyr61, CTGF and NOV in human acute and chronic wounds. Experimental and Therapeutic Medicine 2 (4), pp.641-645. (10.3892/etm.2011.256)
- Mustafa, N. , Martin, T. A. and Jiang, W. G. 2011. Metastasis tumour suppressor-1 and the aggressiveness of prostate cancer cells. Experimental and Therapeutic Medicine 2 (1), pp.157-162. (10.3892/etm.2010.184)
- Sanders, A. J. et al. 2011. EPLIN is a negative regulator of prostate cancer growth and invasion. The Journal of Urology 186 (1), pp.295-301. (10.1016/j.juro.2011.03.038)
2010
- Escudero-Esparza, A. et al. 2010. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncology Reports 23 (2), pp.537-544. (10.3892/or_00000667)
- Herman, F. et al., 2010. Expression of the ERM family members (ezrin, radixin and moesin) in breast cancer. Experimental and Therapeutic Medicine 1 (1), pp.153-160. (10.3892/etm_00000025)
- Lane, J. et al. 2010. The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. Journal of Experimental Therapeutics and Oncology 8 (3), pp.203-210.
- Lane, J. , Martin, T. A. and Jiang, W. G. 2010. Targeting RhoC by way of ribozyme trangene in human breast cancer cells and its impact on cancer invasion. World Journal of Oncology 1 (1), pp.7-13. (10.4021/wjon2010.01.1202)
- Martin, T. A. and Jiang, W. G. 2010. Hepatocyte growth factor and cMET, new development in cancer therapies [Editorial]. Anti-Cancer Agents in Medicinal Chemistry 10 (1), pp.1.
- Martin, T. A. and Jiang, W. G. 2010. Hepatocyte growth factor and its receptor signalling complex as targets in cancer therapy. Anti-Cancer Agents in Medicinal Chemistry 10 (1), pp.2-6.
- Martin, T. A. , Mansel, R. E. and Jiang, W. G. 2010. Loss of occludin leads to the progression of human breast cancer. International Journal of Molecular Medicine 26 (5), pp.723-734. (10.3892/ijmm_00000519)
2009
- Minhas, U. et al. 2009. CCN family proteins in wound healing - a pivotal role? [Abstract]. Wound Repair and Regeneration 17 (4), pp.A74. (10.1111/j.1524-475X.2009.00519.x)
- Escudero-Esparza, A. et al. 2009. PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics and Proteomics 6 (4), pp.239-246.
- Martin, T. A. and Jiang, W. G. 2009. Loss of tight junction barrier function and its role in cancer metastasis. Biochimica et Biophysica Acta (BBA) - Biomembranes 1788 (4), pp.872-891. (10.1016/j.bbamem.2008.11.005)
2008
- Lane, J. et al. 2008. The expression and prognostic value of the guanine nucleotide exchange factors (GEFs) Trio, Vav1 and TIAM-1 in human breast cancer. International Seminars in Surgical Oncology 5 (1) 23. (10.1186/1477-7800-5-23)
- Jiang, W. G. et al. 2008. Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Molecular Cancer 7 71. (10.1186/1476-4598-7-71)
- Lane, J. et al. 2008. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. International Journal of Oncology 33 (3), pp.585-593. (10.3892/ijo_00000044)
- Davies, G. et al. 2008. Phospholipase-C gamma-1 (PLCγ-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells. Urologic Oncology: Seminars and Original Investigations 26 (4), pp.386-391. (10.1016/j.urolonc.2007.06.003)
- Goyal, A. et al. 2008. Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome. World Journal of Surgical Oncology 6 , pp.56-61. (10.1186/1477-7819-6-56)
- Martin, T. A. et al. 2008. Claudin-16 reduces the aggressive behavior of human breast cancer cells. Journal of Cellular Biochemistry 105 (1), pp.41-52. (10.1002/jcb.21797)
- Sanders, A. J. et al. 2008. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. Journal of Cellular Physiology 216 (3), pp.780-789. (10.1002/jcp.21460)
2007
- Parr, C. et al., 2007. Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Clinical Cancer Research 13 (12), pp.3568-3576. (10.1158/1078-0432.CCR-06-2357)
- Martin, T. A. et al. 2007. N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer. Clinical & Experimental Metastasis 25 (2), pp.97-108. (10.1007/s10585-007-9120-8)
2006
- Lane, J. , Martin, T. A. and Jiang, W. G. 2006. Novel protein binding partners for Rho-associated serine-threonine protein kinases (ROCKS) in breast cancer cells [Abstract]. Breast Cancer Research and Treatment 100 (1 Supp), pp.S298-S298. 6127.
- Harrison, G. et al., 2006. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Oncology Reports 15 (1), pp.199-206. (10.3892/or.15.1.199)
- Jiang, W. G. et al. 2006. Com-1/p8 acts as a putative tumour suppressor in prostate cancer. International Journal of Molecular Medicine 18 (5), pp.981-986.
- Sanders, A. J. et al. 2006. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. Journal of Experimental Therapeutics and Oncology 6 (1), pp.39-48.
- Sanders, A. J. et al. 2006. Genetic reduction of matriptase-1 expressionj is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. Journal of Experimental Therapeautics and Oncology 6 (1), pp.39-48.
2005
- Lane, J. , Martin, T. and Jiang, W. G. 2005. Targeting Rho-C by way of ribozyme transgene in human breast cancer cells and its impact on cancer invasion. Breast Cancer Research and Treatment 94 (1), pp.S188-S189. 4068. (10.1007/s10549-005-1234-6)
- Lane, J. , Martin, T. A. and Jiang, W. G. 2005. ROCK inhibitor Y-27632 suppresses the effect of HGF in human breast cancer cells [Abstract]. Breast Cancer Research and Treatment 94 (1 Supp), pp.S193-S194. 4082.
- Jiang, W. G. et al. 2005. Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clinical Cancer Research 11 (16), pp.6012-6019. (10.1158/1078-0432.CCR-05-0275)
- Martin, T. A. et al. 2005. Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin. Histopathology 46 (4), pp.422-430. (10.1111/j.1365-2559.2005.02104.x)
- Jiang, W. et al. 2005. Manipulation of expression of MMP-14 and its impact on the invasivess and progression of breast cancer cells [Abstract]. Breast Cancer Research and Treatment 94 , pp.S187-S187.
- Martin, T. A. et al. 2005. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Annals of Surgical Oncology 12 (6), pp.488-496. (10.1245/ASO.2005.04.010)
2003
- Jiang, W. G. et al. 2003. Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. Clinical Cancer Research 9 (11), pp.4274-4281.
- Martin, T. A. et al. 2003. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 24 (8), pp.1317-1323. (10.1093/carcin/bgg072)
- Davies, G. et al., 2003. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesisin vivo. International Journal of Cancer 106 (3), pp.348-354. (10.1002/ijc.11220)
2001
- Jiang, W. G. et al. 2001. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clinical Cancer Research 7 , pp.2555-2562.
- Martin, T. A. , Harding, K. G. and Jiang, W. G. 2001. Matrix-bound fibroblasts regulate angiogenesis by modulation of VE-cadherin. European Journal of Clinical Investigation 31 (11), pp.931-938. (10.1046/j.1365-2362.2001.00914.x)
- Martin, T. A. and Jiang, W. G. 2001. Tight junctions and their role in cancer metastasis.. Histology and Histopathology 16 , pp.1183-1195.
- Martin, T. A. , Mansel, R. E. and Jiang, W. G. 2001. Hepatocyte growth factor modulates vascular endothelial-cadherin expresssion in human endothelial cells. Clinical Cancer Research 7 (3), pp.734-737.
1999
- Jiang, W. G. et al. 1999. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clinical Cancer Research 5 (11), pp.3695-3703.
- Jiang, W. G. et al. 1999. Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells.. Journal of Cellular Physiology 181 (2), pp.219-329. (10.1002/(SICI)1097-4652(199911)181:2<319::AID-JCP14>3.0.CO;2-S)
Adrannau llyfrau
- Martin, T. A. et al. 2013. Cancer invasion and metastasis: molecular and cellular perspective. In: Jandial, R. ed. Metastatic Cancer Clinical and Biological Perspectives. Austin, TX: Landes Bioscience. , pp.135-168.
Cynadleddau
- Tian, Q. et al. 2026. Iteratively calibrated s11 thermometry for microsecond-scale intra-pulse heating in 96-well plates. Presented at: 2026 IEEE MTT-S Radio Frequency Systems and Applications Symposium (IMS RFSA) Boston, MA, USA 7-12 June 2026. 2026 IEEE MTT-S Radio Frequency Systems and Applications Symposium (IMS RFSA). IEEE. , pp.430-433. (10.1109/imsrfsa70221.2026.11624232)
- Zhao, Z. et al. 2020. Abstract P2-07-01: Kidins220 (kinase D interacting substrate 220) has a connection with neutrotrophic related factors, BDNF and NGF, in human breast cancer. Presented at: San Antonio Breast Cancer Symposium San Antonio, TX, United States 10-14 December 2019. Vol. 80.Vol. 4, Sup. , pp.P2-07-01. (10.1158/1538-7445.SABCS19-P2-07-01)
- Zhao, Z. et al. 2020. Abstract P3-01-18: Kinase D interacting substrate 220 (Kidins220) and disease progression of breast cancer, the role of heat shock protein90 (HSP90). Presented at: San Antonio Breast Cancer Symposium San Antonio, TX, United States 10-14 December 2019. Vol. 80.Vol. 4, Sup. American Association for Cancer Research. , pp.P3-01-18. (10.1158/1538-7445.SABCS19-P3-01-18)
Erthyglau
- Xu, Z. et al., 2026. SLC27, Solute Carrier 27 family, a long-chain fatty acid membrane transporters, in human cancers. Frontiers in Cell and Developmental Biology 14 1839021. (10.3389/fcell.2026.1839021)
- Sun, Z. , Martin, T. A. and Jiang, W. G. 2026. Exploring nonviral nanocarriers as RNA delivery platforms for the treatment of breast cancer. Chemical Engineering Journal 538 176496. (10.1016/j.cej.2026.176496)
- Jiao, J. , Martin, T. A. and Jiang, W. 2026. Beyond barrier function: Tight junctions as dynamic signaling hubs orchestrating tumor plasticity, microenvironment remodeling, and metastatic evolution. Immune Discovery 2 (2) 10004. (10.70322/immune.2026.10004)
- Yao, H. et al., 2026. Molecular mechanisms and therapeutic targeting implications of ER/mTOR signaling axis-driven tumor progression in aggressive meningiomas. Translational Oncology 66 102723. (10.1016/j.tranon.2026.102723)
- Xiang, H. et al. 2026. SRS123 - Clinical relevance of MarvelD2 as a prognostic biomarker in clinical breast cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.119. (10.1093/bjs/znag018.119)
- Chen, D. Y. et al., 2026. SRS387 - MLN64/StarD3 and StarD3NL in pancreatic cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.343. (10.1093/bjs/znag018.343)
- Li, A. X. et al. 2026. SRS126 - MLN64 and StarD3NL highly correlated with the autophagy marker SQSTM1 and BECN1 in breast cancer, and indicate prognostic and therapeutic potential [Abstract]. British Journal of Surgery 113 (S2) znag018.122. (10.1093/bjs/znag018.122)
- O’Neill, N. et al. 2026. SRS359 - A novel association between disialoganglioside (GD2), GD2 synthesising enzymes and the Angiomotin family in breast cancer [Abstract]. British Journal of Surgery 113 (S2) znag018.318. (10.1093/bjs/znag018.318)
- Sun, Z. , Jiang, W. and Martin, T. 2026. SRS127 - Afadin (AFDN) and the nectin protein complex in the development of metastasis of breast cancers [Abstravt]. British Journal of Surgery 113 (S2) znag018.123. (10.1093/bjs/znag018.123)
- Xiang, H. et al. 2026. SRS133 - Nucleolin (NCL) in clinical breast cancer, the prognostic and therapeutic implications [Abstract]. British Journal of Surgery 113 (S2) znag018.129. (10.1093/bjs/znag018.129)
- Cong, B. et al., 2026. MLN51 (Metastatic Lymph Node Gene 51)/CASC3 (Cancer Susceptibility Candidate Gene 3), A putative tumour suppressor in breast cancer, the clinical and therapeutic connections. Breast Cancer: Targets and Therapy 18 (2026), pp.1-17. (10.2147/BCTT.S565199)
- Cong, B. et al., 2026. MLN51 (metastatic lymph node gene 51)/CASC3 (cancer susceptibility candidate gene 3), a putative tumour suppressor in breast cancer, the clinical and therapeutic connections. Breast Cancer: Targets and Therapy 18 (10.2147/bctt.s565199)
- Li, A. X. et al. 2026. Targeting the MLN64/STARD3-cholesterol axis disrupts tight junction remodelling and attenuates gastric cancer aggressiveness. Frontiers in Oncology (10.3389/fonc.2026.1913732)
- Zhu, K. et al., 2025. Tumor exosomal miR-221-3p induces glycolysis through the LIFR/GLUT1 pathway to destroy the cerebral vascular endothelial cell barrier and promote breast cancer brain metastasis. Journal of Translational Medicine 23 (1) 1333. (10.1186/s12967-025-07372-8)
- Wazir, U. et al., 2025. CD84 as a prognostic biomarker and therapeutic target in breast cancer: Interconnections with PDL1, CD74, and immune tolerance mechanisms. Cancer Genomics & Proteomics 22 (4), pp.557-563. (10.21873/cgp.20521)
- Ji, W. et al. 2025. Tight junctional protein family, Claudins in cancer and cancer metastasis. Frontiers in Oncology 15 1596460. (10.3389/fonc.2025.1596460)
- Ji, W. et al. 2025. Knockdown of claudin-8 (CLDN8) indicates a link between breast cancer cell sensitivity to chemotherapeutics and reveals a potential use of CLDN8 as a molecular diagnostic and target for therapy. International Journal of Molecular Sciences 26 (11) 5412. (10.3390/ijms26115412)
- Yu, R. Y. , Jiang, W. G. and Martin, T. A. 2025. The WASP/WAVE protein family in breast cancer and their role in the metastatic cascade. Cancer Genomics & Proteomics 22 (2), pp.166-187. (10.21873/cgp.20495)
- Tong, J. et al. 2025. DRIM modulates Src activation and regulates angiogenic functions in vascular endothelial cells. Cell Biology International 49 (3), pp.277-287. (10.1002/cbin.12265)
- O’Neill, N. S. et al. 2025. Correlation of GD2 biosynthesis enzymes with cancer stem cell markers in human breast cancer. Cancer Genomics & Proteomics 22 (2), pp.231-246. (10.21873/cgp.20498)
- Zeng, J. et al. 2024. EPLIN, a prospective oncogenic molecule with contribution to growth, migration and drug resistance in pancreatic cancer. Scientific Reports 14 (1) 30850. (10.1038/s41598-024-81485-w)
- Zhu, K. et al., 2024. Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway. Journal of Neuro-Oncology 170 , pp.331-345. (10.1007/s11060-024-04797-x)
- Li, A. X. et al. 2024. Metastatic Lymph Node 64 (MLN64) expression in gastric cancer, the clinical and molecular implications in drug resistance. Cancer Genomics & Proteomics 21 (1), pp.30-40. (10.21873/cgp.20427)
- Li, A. X. et al., 2024. Cellular impacts of striatins and the STRIPAK complex and their roles in the development and metastasis in clinical cancers. Cancers 16 (1) 76. (10.3390/cancers16010076)
- Zhuang, X. et al., 2023. Expression of Claudin-9 (CLDN9) in breast cancer, the clinical significance in connection with its subcoat anchorage proteins ZO-1 and ZO-3 and impact on drug resistance. Biomedicines 11 (12) 3136. (10.3390/biomedicines11123136)
- Zhuang, X. et al. 2023. Claudin-10 in the blood brain barrier function of cerebral endothelial cells and transendothelial invasion of breast cancer cells. Anticancer Research 43 (9), pp.3923-3934. (10.21873/anticanres.16580)
- Frugtniet, B. A. et al. 2023. nWASP inhibition increases wound healing via TrKb/PLCγ signalling. Biomolecules 13 (2) 379. (10.3390/biom13020379)
- Li, A. X. et al. 2023. Striatins and the STRIPAK complex partners in the clinical outcome of patients with breast cancer and responses to drug treatment. Chinese Journal of Cancer Research 35 , pp.365-385. (10.21147/j.issn.1000-9604.2023.04.04)
- Sui, L. et al. 2022. Death associated protein-3 (DAP3) and DAP3 binding cell death enhancer-1 (DELE1) in human colorectal cancer, and their impacts on clinical outcome and chemoresistance. International Journal of Oncology 62 (1) 7. (10.3892/ijo.2022.5455)
- Gao, H. et al., 2022. P-211 Claudin-16, its clinical and prognostic value in colorectal cancer. Annals of Oncology 33 , pp.S324-S324. (10.1016/j.annonc.2022.04.301)
- Sui, L. et al. 2022. P-282 Impact of death-associated protein-3 (DAP3) and DAP3 binding cell death enhancer 1 (DELE1) on drug sensitivity in colorectal cancer cells. Annals of Oncology 33 , pp.S347. (10.1016/j.annonc.2022.04.371)
- Telford, E. A. et al. 2022. Hepatitis A virus cellular receptor 1 (HAVcr-1) initiates prostate cancer progression in human cells via hepatocyte growth factor (HGF)-induced changes in junctional integrity. Biomolecules 12 (2) 338. (10.3390/biom12020338)
- Xin, L. et al., 2021. SIKs suppress tumor function and regulate drug resistance in breast cancer. American Journal of Cancer Research 11 (7), pp.3537-3557.
- Martin, T. A. et al. 2021. NUPR1 and its potential role in cancer and pathological conditions (Review). International Journal of Oncology 58 (5) 21. (10.3892/ijo.2021.5201)
- Liu, C. et al. 2021. SIPA1 Is a modulator of HGF/MET induced tumour metastasis via the regulation of tight junction-based cell to cell barrier function. Cancers 13 (7) 1747. (10.3390/cancers13071747)
- Gong, W. et al., 2021. Location, function and role of stromal cell-derived factors and possible implications in cancer. International Journal of Molecular Medicine 47 (2), pp.435-443. (10.3892/ijmm.2020.4811)
- Gong, W. et al., 2020. Influence of anaesthetics on the production of cancer cell motogens, stromal cell-derived factor-1 and hepatocyte growth factor by fibroblasts. Oncology Letters 21 (2) 140. (10.3892/ol.2020.12401)
- Liu, C. et al. 2020. The role of SIPA1 in the development of cancer and metastases (Review). Molecular and Clinical Oncology 13 (4) 32. (10.3892/mco.2020.2102)
- Cong, Y. et al., 2020. Tim-3 promotes cell aggressiveness and paclitaxel resistance through the NF-κB /STAT3 signalling pathway in breast cancer cells. Chinese Journal of Cancer Research 32 (5), pp.564-579. (10.21147/j.issn.1000-9604.2020.05.02)
- Wazir, U. et al., 2020. Stratification using hTERT and stem cell markers confers a good prognosis in invasive breast cancer. Cancer Genomics and Proteomics 17 (2), pp.169-174. (10.21873/cgp.20177)
- Xu, Y. et al., 2019. BDNF activates TrkB/PLCγ1 signaling pathway to promote proliferation and invasion of ovarian cancer cells through inhibition of apoptosis. European Review for Medical and Pharmacological Sciences 23 (12), pp.5093-5100. (10.26355/eurrev_201906_18173)
- Wazir, U. et al., 2019. Correlation of TERT and stem cell markers in the context of human breast cancer. Cancer Genomics and Proteomics 16 (2), pp.121-127. (10.21873/cgp.20117)
- Jia, J. et al., 2018. Fibroblast activation protein-α promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways. International Journal of Molecular Medicine 41 (1), pp.275-283. (10.3892/ijmm.2017.3224)
- Xin, L. et al. 2017. The era of multigene panels comes? The clinical utility of Oncotype DX and MammaPrint. World Journal of Oncology 8 (2), pp.34-40. (10.14740/wjon1019w)
- Zhao, H. et al., 2017. The effect of aurora kinase inhibitor on adhesion and migration in human breast cancer cells and clinical implications. World Journal of Oncology 8 (5), pp.151-161. (10.14740/wjon1062w)
- Ismail, A. F. et al., 2017. PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells. Biochemical Journal 474 (8), pp.1333-1346. (10.1042/BCJ20160875)
- Frugtniet, B. A. et al. 2017. Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion. BMC Cancer 17 (1) 224. (10.1186/s12885-017-3219-3)
- Yang, X. et al., 2017. A novel NHERF1 mutation in human breast cancer and effects on malignant progression. Anticancer Research 37 (1), pp.67-73. (10.21873/anticanres.11290)
- Gu, Y. et al., 2017. NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway. Oncotarget 8 (5), pp.7753-7765. (10.18632/oncotarget.13949)
- Telford, E. , Jiang, W. G. and Martin, T. A. 2017. HAVcR-1 involvement in cancer progression. Histology and Histopathology 32 , pp.121-128. (10.14670/HH-11-817)
- Liu, R. et al., 2016. Epithelial protein lost in neoplasm-α (EPLIN-α) is a potential prognostic marker for the progression of epithelial ovarian cancer. International Journal of Oncology 48 (6), pp.2488-2496. (10.3892/ijo.2016.3462)
- Zhao, H. et al. 2016. The role of JAM-B in cancer and cancer metastasis (Review). Oncology Reports 36 , pp.3-9. (10.3892/or.2016.4773)
- Martin, T. A. et al. 2016. Metastasis to bone in human cancer is associated with loss of occludin expression. Anticancer Research 36 (3), pp.1287-1294.
- Yang, X. et al., 2016. The impact of TIMM17A on aggressiveness of human breast cancer cells. Anticancer Research 36 (3), pp.1237-1241.
- Zhao, H. et al. 2016. The clinical implications of RSK1-3 in human breast cancer. Anticancer Research 36 (3), pp.1267-1274.
- Zhao, H. et al. 2016. Effect of junctional adhesion molecule-2 expression on cell growth, invasion and migration in human colorectal cancer. International Journal of Oncology 48 (3), pp.929-936. (10.3892/ijo.2016.3340)
- Jia, W. et al., 2016. Expression of the Epithelial-Mesenchymal-Transition (EMT) markers, Twist, Slug, Snail, E- and N-cadherins and the association with clinical and pathological features of human pituitary adenomas [Abstract]. European Journal of Cancer 51 (S3), pp.S592-S593. 2925. (10.1016/S0959-8049(15)30055-1)
- Liu, R. et al., 2015. Metastasis suppressor 1 expression in human ovarian cancer: the impact on cellular migration and metastasis. International Journal of Oncology 47 (4), pp.1429-1439. (10.3892/ijo.2015.3121)
- Tan, Y. et al., 2015. Interleukin-24 (IL-24) expression and biological impact on HECV endothelial cells.. Cancer Genomics and Proteomics 12 (5), pp.243-250.
- Owen, S. et al., 2015. An investigation of Amphiphysin II transcript expression in pituitary adenomas [Abstract]. European Journal of Cancer 51 (S3), pp.S580-S580. 2806. (10.1016/S0959-8049(15)30053-8)
- Owen, S. et al., 2015. The prostate Transglutaminase, TGase-4, is potentially linked to the junctional proteins at tight junctions of prostate tissues and prostate cancer cells [Abstract]. European Journal of Cancer 51 (S3), pp.S481. 2516. (10.1016/S0959-8049(15)30048-4)
- Jiang, W. G. et al. 2015. YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells. Journal of Translational Medicine 13 280. (10.1186/s12967-015-0639-1)
- Ali, A. Y. et al. 2015. Anti-metastatic and cytotoxic properties of frankincense and scented myrrh. Anticancer Research 35 (7), pp.4310-4311.
- Fang, X. , Jiang, W. G. and Martin, T. A. 2015. The role of claudin-5 in the cell-cell adhesion of human keratinocytes. Anticancer Research 35 (7), pp.4367.
- Frugtniet, B. , Jiang, W. G. and Martin, T. A. 2015. Investigating the effect of NWASP (Neural Wiskott-Aldrich Syndrome Protein) inhibitors on human lung cancer cell behaviour. Anticancer Research 35 (7), pp.4348-4349.
- Jia, W. et al., 2015. Association of mta-1 expression in pituitary tumours with bone invasion. Anticancer Research 35 (7), pp.4360.
- Liu, R. et al., 2015. Metastasis suppressor 1 (MTSS1) expression in human ovarian cancer; the impact on cellular migration and metastasis [Abstract]. Anticancer Research 35 (7), pp.4342-4342.
- Martin, T. A. et al. 2015. Comparison of blood brain barrier endothelia reveals a differential expression of tight junction proteins [Abstract]. Anticancer Research 35 (7), pp.4357-4358.
- Martin, T. A. , Telford, E. and Jiang, W. G. 2015. HAVCR1 is a potential prognostic factor in human breast cancer. Anticancer Research 35 (7), pp.4327.
- Martin, T. A. and Tiang, W. G. 2015. The blood brain barrier and the prevention of metastatic disease. Anticancer Research 35 (7), pp.4298-4299.
- Jia, W. et al., 2015. Expression of metastasis-associated gene-1 is associated with bone invasion and tumor stage in human pituitary adenomas. Cancer Genomics and Proteomics 12 (3), pp.113-118.
- Frugtniet, B. , Jiang, W. G. and Martin, T. A. 2015. Role of the WASP and WAVE family proteins in breast cancer invasion and metastasis. Breast Cancer: Targets and Therapy 2015 (7), pp.99-109. (10.2147/BCTT.S59006)
- Jia, W. et al., 2015. Epithelial-mesenchymal transition (EMT) markers in human pituitary adenomas indicate a clinical course. Anticancer Research 35 (5), pp.2635-2643.
- Men, W. et al., 2015. Expression of claudins in human clear cell renal cell carcinoma. Cancer Genomics and Proteomics 12 (1), pp.1-8.
- Martin, T. A. 2014. The role of tight junctions in cancer metastasis. Seminars in Cell and Developmental Biology 36 , pp.224-231. (10.1016/j.semcdb.2014.09.008)
- Martin, T. A. et al. 2014. Brain-derived neurotrophic factor (bdnf) is a novel therapeutic agent in human wound healing [Abstract]. Wound Repair and Regeneration 22 (5), pp.A91. (10.1111/wrr.12218)
- Ye, L. et al. 2014. Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumour-related angiogenesis. International Journal of Oncology 45 (4), pp.1565-1573. (10.3892/ijo.2014.2533)
- Martin, T. A. , Mason, M. D. and Jiang, W. G. 2014. HGF and the regulation of tight junctions in human prostate cancer cells. Oncology Reports 32 (1), pp.213-224. (10.3892/or.2014.3219)
- Jia, W. et al., 2014. The role of claudin-5 in blood-brain barrier ( BBB) and brain metastases (Review). Molecular Medicine Reports 9 (3), pp.779-785. (10.3892/mmr.2013.1875)
- Sun, T. T. et al., 2014. Disrupted interaction between CFTR and AF-6/afadin aggravates malignant phenotypes of colon cancer. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1843 (3), pp.618-628. (10.1016/j.bbamcr.2013.12.013)
- Feng, X. et al., 2014. Regulation and involvement in cancer and pathological conditions of MAGI1, a tight junction protein. Anticancer Research 34 (7), pp.3251-3256.
- Frugtniet, B. et al. 2014. nWASP (neural Wiskott-Aldrich syndrome protein) is a novel therapeutic target in human wound healing [Conference Abstract]. Wound Repair and Regeneration 22 (5), pp.A80-A80. (10.1111/wrr.12218)
- Jia, J. et al., 2014. FAP-alpha (Fibroblast activation protein-alpha) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biology 15 16. (10.1186/1471-2121-15-16)
- Lane, J. et al. 2014. Structure and role of WASP and WAVE in Rho GTPase signalling in cancer. Cancer Genomics and Proteomics 11 (3), pp.155-165.
- Martin, T. A. and Jiang, W. G. 2014. Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma. Oncology Reports 31 (1), pp.262-272. (10.3892/or.2013.2813)
- Martin, T. A. et al. 2013. The expression of the Nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis. PLoS ONE 8 (12) e82696. (10.1371/journal.pone.0082696)
- Martin, T. A. and Jiang, W. G. 2013. Regulation of barrier function in human breast cancer can be controlled by the ROCK signalling pathway via interaction with SIPA-1 [Abstract]. European Journal of Cancer 49 , pp.S132-S132.
- Martin, T. A. et al. 2013. Claudin-20 promotes an aggressive phenotype in human breast cancer cells. Tissue Barriers 1 (3) e26518. (10.4161/tisb.26518)
- Martin, T. A. , Mason, M. D. and Jiang, W. G. 2013. HGF and the regulation of tight junctions in human prostate cancer cells [Abstract]. European Journal of Cancer 49 , pp.S132-S132.
- Wang, Y. , Martin, T. A. and Jiang, W. G. 2013. HAVcR-1 expression in human colorectal cancer and its effects on colorectal cancer cells in vitro.. Anticancer Research 33 (1), pp.207-214.
- Yang, X. , Martin, T. A. and Jiang, W. G. 2013. Biological influence of brain-derived neurotrophic factor (BDNF) on colon cancer cells. Experimental and Therapeutic Medicine 6 (6), pp.1475-1481. (10.3892/etm.2013.1330)
- Ye, L. et al. 2013. Psoriasin (S100A7) is a positive regulator of survival and invasion of prostate cancer cells. Urologic Oncology: Seminars and Original Investigations 31 (8), pp.1576-1583. (10.1016/j.urolonc.2012.05.006)
- Escudero-Esparza, A. , Jiang, W. G. and Martin, T. A. 2012. Claudin-5 is involved in breast cancer cell motility through the N-WASP and ROCK signalling pathways. Journal of Experimental & Clinical Cancer Research 31 (1), pp.43-60. (10.1186/1756-9966-31-43)
- Ji, K. et al. 2012. Expression of signal-induced proliferation-associated gene 1 (SIPA1), a rapGTPase-activating protein, is increased in colorectal cancer and has diverse effects on functions of colorectal cancer cells. Cancer Genomics and Proteomics 9 (5), pp.321-327.
- Li, X. , Martin, T. A. and Jiang, W. G. 2012. COM-1/p8 acts as a tumour growth enhancer in colorectal cancer cell lines. Anticancer Research 32 (4), pp.1229-1237.
- Martin, T. A. et al. 2012. The clinical and biological implications of N-WASP expression in human colorectal cancer. Translational Gastrointestinal Cancer 1 (1), pp.10-20.
- Yang, X. , Martin, T. A. and Jiang, W. G. 2012. Biological influence of brain-derived neurotrophic factor on breast cancer cells. International Journal of Oncology 41 (4), pp.1541-1546. (10.3892/ijo.2012.1581)
- Martin, T. A. et al. 2011. HAVcR-1 reduces the integrity of human endothelial tight junctions. Anticancer Research 31 (2), pp.467-473.
- Awsare, N. S. et al. 2011. Claudin-11 decreases the invasiveness of bladder cancer cells. Oncology Reports 25 (6), pp.1503-1509. (10.3892/or.2011.1244)
- Cheng, S. et al., 2011. Putative breast tumor suppressor TACC2 suppresses the aggressiveness of breast cancer cells through a PLCγ pathway. Current Signal Transduction Therapy 6 (1), pp.55-64. (10.2174/157436211794109361)
- Escudero-Esparza, A. , Jiang, W. G. and Martin, T. A. 2011. Claudin-5 participates in the regulation of endothelial cell motility. Molecular and Cellular Biochemistry 362 (1-2), pp.71-85. (10.1007/s11010-011-1129-2)
- Escudero-Esparza, A. , Jiang, W. G. and Martin, T. A. 2011. The Claudin family and its role in cancer and metastasis. Frontiers in Bioscience 16 (3), pp.1069-1083. (10.2741/3736)
- Lane, J. , Martin, T. A. and Jiang, W. G. 2011. HGF and rhoGTPases in cancer cell motility. Current Signal Transduction Therapy 6 (2), pp.173-179. (10.2174/157436211795660052)
- Martin, T. A. , Mason, M. D. and Jiang, W. G. 2011. Hepatocyte growth factor signalling in cancer metastasis. Current Signal Transduction Therapy 6 (2), pp.180-190. (10.2174/157436211795659991)
- Martin, T. A. , Mason, M. D. and Jiang, W. G. 2011. Tight junctions in cancer metastasis. Frontiers in Bioscience 16 (3), pp.898-936. (10.2741/3726)
- Minhas, U. et al. 2011. Pattern of expression of CCN family members Cyr61, CTGF and NOV in human acute and chronic wounds. Experimental and Therapeutic Medicine 2 (4), pp.641-645. (10.3892/etm.2011.256)
- Mustafa, N. , Martin, T. A. and Jiang, W. G. 2011. Metastasis tumour suppressor-1 and the aggressiveness of prostate cancer cells. Experimental and Therapeutic Medicine 2 (1), pp.157-162. (10.3892/etm.2010.184)
- Sanders, A. J. et al. 2011. EPLIN is a negative regulator of prostate cancer growth and invasion. The Journal of Urology 186 (1), pp.295-301. (10.1016/j.juro.2011.03.038)
- Escudero-Esparza, A. et al. 2010. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncology Reports 23 (2), pp.537-544. (10.3892/or_00000667)
- Herman, F. et al., 2010. Expression of the ERM family members (ezrin, radixin and moesin) in breast cancer. Experimental and Therapeutic Medicine 1 (1), pp.153-160. (10.3892/etm_00000025)
- Lane, J. et al. 2010. The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. Journal of Experimental Therapeutics and Oncology 8 (3), pp.203-210.
- Lane, J. , Martin, T. A. and Jiang, W. G. 2010. Targeting RhoC by way of ribozyme trangene in human breast cancer cells and its impact on cancer invasion. World Journal of Oncology 1 (1), pp.7-13. (10.4021/wjon2010.01.1202)
- Martin, T. A. and Jiang, W. G. 2010. Hepatocyte growth factor and cMET, new development in cancer therapies [Editorial]. Anti-Cancer Agents in Medicinal Chemistry 10 (1), pp.1.
- Martin, T. A. and Jiang, W. G. 2010. Hepatocyte growth factor and its receptor signalling complex as targets in cancer therapy. Anti-Cancer Agents in Medicinal Chemistry 10 (1), pp.2-6.
- Martin, T. A. , Mansel, R. E. and Jiang, W. G. 2010. Loss of occludin leads to the progression of human breast cancer. International Journal of Molecular Medicine 26 (5), pp.723-734. (10.3892/ijmm_00000519)
- Minhas, U. et al. 2009. CCN family proteins in wound healing - a pivotal role? [Abstract]. Wound Repair and Regeneration 17 (4), pp.A74. (10.1111/j.1524-475X.2009.00519.x)
- Escudero-Esparza, A. et al. 2009. PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics and Proteomics 6 (4), pp.239-246.
- Martin, T. A. and Jiang, W. G. 2009. Loss of tight junction barrier function and its role in cancer metastasis. Biochimica et Biophysica Acta (BBA) - Biomembranes 1788 (4), pp.872-891. (10.1016/j.bbamem.2008.11.005)
- Lane, J. et al. 2008. The expression and prognostic value of the guanine nucleotide exchange factors (GEFs) Trio, Vav1 and TIAM-1 in human breast cancer. International Seminars in Surgical Oncology 5 (1) 23. (10.1186/1477-7800-5-23)
- Jiang, W. G. et al. 2008. Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Molecular Cancer 7 71. (10.1186/1476-4598-7-71)
- Lane, J. et al. 2008. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. International Journal of Oncology 33 (3), pp.585-593. (10.3892/ijo_00000044)
- Davies, G. et al. 2008. Phospholipase-C gamma-1 (PLCγ-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells. Urologic Oncology: Seminars and Original Investigations 26 (4), pp.386-391. (10.1016/j.urolonc.2007.06.003)
- Goyal, A. et al. 2008. Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome. World Journal of Surgical Oncology 6 , pp.56-61. (10.1186/1477-7819-6-56)
- Martin, T. A. et al. 2008. Claudin-16 reduces the aggressive behavior of human breast cancer cells. Journal of Cellular Biochemistry 105 (1), pp.41-52. (10.1002/jcb.21797)
- Sanders, A. J. et al. 2008. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. Journal of Cellular Physiology 216 (3), pp.780-789. (10.1002/jcp.21460)
- Parr, C. et al., 2007. Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Clinical Cancer Research 13 (12), pp.3568-3576. (10.1158/1078-0432.CCR-06-2357)
- Martin, T. A. et al. 2007. N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer. Clinical & Experimental Metastasis 25 (2), pp.97-108. (10.1007/s10585-007-9120-8)
- Lane, J. , Martin, T. A. and Jiang, W. G. 2006. Novel protein binding partners for Rho-associated serine-threonine protein kinases (ROCKS) in breast cancer cells [Abstract]. Breast Cancer Research and Treatment 100 (1 Supp), pp.S298-S298. 6127.
- Harrison, G. et al., 2006. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Oncology Reports 15 (1), pp.199-206. (10.3892/or.15.1.199)
- Jiang, W. G. et al. 2006. Com-1/p8 acts as a putative tumour suppressor in prostate cancer. International Journal of Molecular Medicine 18 (5), pp.981-986.
- Sanders, A. J. et al. 2006. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. Journal of Experimental Therapeutics and Oncology 6 (1), pp.39-48.
- Sanders, A. J. et al. 2006. Genetic reduction of matriptase-1 expressionj is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. Journal of Experimental Therapeautics and Oncology 6 (1), pp.39-48.
- Lane, J. , Martin, T. and Jiang, W. G. 2005. Targeting Rho-C by way of ribozyme transgene in human breast cancer cells and its impact on cancer invasion. Breast Cancer Research and Treatment 94 (1), pp.S188-S189. 4068. (10.1007/s10549-005-1234-6)
- Lane, J. , Martin, T. A. and Jiang, W. G. 2005. ROCK inhibitor Y-27632 suppresses the effect of HGF in human breast cancer cells [Abstract]. Breast Cancer Research and Treatment 94 (1 Supp), pp.S193-S194. 4082.
- Jiang, W. G. et al. 2005. Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clinical Cancer Research 11 (16), pp.6012-6019. (10.1158/1078-0432.CCR-05-0275)
- Martin, T. A. et al. 2005. Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin. Histopathology 46 (4), pp.422-430. (10.1111/j.1365-2559.2005.02104.x)
- Jiang, W. et al. 2005. Manipulation of expression of MMP-14 and its impact on the invasivess and progression of breast cancer cells [Abstract]. Breast Cancer Research and Treatment 94 , pp.S187-S187.
- Martin, T. A. et al. 2005. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Annals of Surgical Oncology 12 (6), pp.488-496. (10.1245/ASO.2005.04.010)
- Jiang, W. G. et al. 2003. Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. Clinical Cancer Research 9 (11), pp.4274-4281.
- Martin, T. A. et al. 2003. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 24 (8), pp.1317-1323. (10.1093/carcin/bgg072)
- Davies, G. et al., 2003. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesisin vivo. International Journal of Cancer 106 (3), pp.348-354. (10.1002/ijc.11220)
- Jiang, W. G. et al. 2001. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clinical Cancer Research 7 , pp.2555-2562.
- Martin, T. A. , Harding, K. G. and Jiang, W. G. 2001. Matrix-bound fibroblasts regulate angiogenesis by modulation of VE-cadherin. European Journal of Clinical Investigation 31 (11), pp.931-938. (10.1046/j.1365-2362.2001.00914.x)
- Martin, T. A. and Jiang, W. G. 2001. Tight junctions and their role in cancer metastasis.. Histology and Histopathology 16 , pp.1183-1195.
- Martin, T. A. , Mansel, R. E. and Jiang, W. G. 2001. Hepatocyte growth factor modulates vascular endothelial-cadherin expresssion in human endothelial cells. Clinical Cancer Research 7 (3), pp.734-737.
- Jiang, W. G. et al. 1999. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clinical Cancer Research 5 (11), pp.3695-3703.
- Jiang, W. G. et al. 1999. Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells.. Journal of Cellular Physiology 181 (2), pp.219-329. (10.1002/(SICI)1097-4652(199911)181:2<319::AID-JCP14>3.0.CO;2-S)
Ymchwil
Cyffyrdd celloedd fel cyfryngwyr neu rwystrau i ledaenu celloedd a'r rheoleiddwyr ohono
- Mae'r Cyffordd Dynn (TJ) yn rhanbarth lle mae pilen plasma celloedd cyfagos yn ffurfio cyfres o gysylltiadau sy'n ymddangos eu bod yn atal y gofod allgellog yn llwyr gan greu rhwystr rhynggellog a ffens trylediad intramembrane.
- Mewn celloedd epithelaidd, mae'r TJ yn gweithredu mewn modd gludiog a gall atal datgysylltu celloedd tra bod TJs mewn celloedd endothelaidd yn gweithredu fel rhwystr lle gall moleciwlau a chelloedd llidiol basio.
- Mae corff sylweddol o waith bellach yn bodoli ar TJ a'u rôl mewn nifer o glefydau.
- Mae TJs wedi cael eu cydnabod fel chwaraewyr allweddol mewn metastasis canser. Awgrymodd astudiaethau cynnar fod cysylltiad rhwng lleihau proteinau TJ a gwahaniaethu tiwmorau a chynyddu tystiolaeth arbrofol wedi dod i'r amlwg i osod TJs yn y rheng flaen fel y strwythur y mae'n rhaid i gelloedd canser ei oresgyn er mwyn metastasize.
- Mae rhyngweithio a threiddiad yr endotheliwm fasgwlaidd gan gelloedd canser datgysylltiol yn gam pwysig wrth ffurfio metastases canser.
- Mae angen newidiadau mewn celloedd tiwmor ac endothelaidd ar gyfer twf a lledaeniad celloedd canser yn llwyddiannus a bod y newidiadau hyn ychydig yn debyg.
- Mae newid mewn celloedd canser trwy uwchreoleiddio neu isreoleiddio proteinau TJ perthnasol yn arwain at golli cysylltiad celloedd-gell, atal cyswllt celloedd, gan arwain at dwf heb reolaeth, colli adlyniad i'r islawr a diraddio.
- Rhaid i'r rhain fod yn golled gydamserol o gysylltiad cell-gell yn endotheliwm a modwleiddio proteinau TJ sy'n ymwneud â hwyluso hynt y celloedd canser trwy'r rhwystr hwn.
- Rydym wedi dangos bod mynegiant gwahaniaethol o nifer o broteinau TJ trawsmembrane, yn enwedig Occludin, Claudin-5 a'r Nectin a'u bod yn cydberthyn ag aflonyddwch TJs mewn tiwmorau.
- Mae modiwleiddio mynegiant o'r proteinau hyn yn arwain at newidiadau allweddol mewn swyddogaeth rhwystr gan arwain at ddilyniant canser a dilyniant metastasis.
Meysydd ymchwil
Triniaethau minimally ymledol:
- Technoleg therapiwtig lleiaf ymledol newydd
rhwystr ymennydd gwaed (BBB):
- Modulators o ddynameg BBB
- Cymhariaeth o wahanol gelloedd endothelaidd BBB a rôl HGF mewn metastasis ymennydd.
HAVcR-1:
- Swyddogaeth HAVcR-1 mewn canser y fron a'i reolaeth ar swyddogaeth rhwystr.
- HAVcR-1 fel modulator sylweddol o signalau HGF mewn metastasis canser y prostad trwy reoli TJs.
Occludin ac MARVELD3:
- Rheoli swyddogaeth TJ gan Occludin / MARVELD3 ac isofformau gwahanol mewn metastasis canser y fron a colorectal.
Arwyddion a rheolaeth ar TJs:
- Sut mae SIPA-1 wedi'i integreiddio i lwybr signalau HGF swyddogaeth TJ mewn canser y fron.
- Archwilio aelodau teulu N-Wasp a WAVE yn swyddogaeth TJ a metastasis.
- BDNf / NGF a'r rhaeadr metastatig.
Addysgu
Goruchwyliaeth ymchwil israddedig:
- Elfen SSC o flwyddyn 1, 2, 3 a 4 C21 MB BCh, lleoliadau ymchwil a dewisol
- Lleoliadau prosiect ymchwil PTY ac ad hoc
- Prosiectau rhyng-gyfrifedig
- Prosiectau Ffarmacoleg Feddygol
Addysgu israddedig:
- Prosiect Llenyddiaeth SSC blwyddyn 1 C21 MB BCh
- PCS blwyddyn 1 C21 MB BCh
Addysgu ôl-raddedig:
- MSc Canser a Therapeutics
- MSc yn goruchwylio prosiect
Bywgraffiad
Trosolwg gyrfa
Darllenydd 2026-cyfredol: Mae fy ffocws ymchwil cyfredol yn parhau i fod ar Tight Junctions a moleciwlau cysylltiedig sy'n ymwneud â metastasis canser, yn enwedig mecanweithiau sy'n llywodraethu rhyngweithiadau celloedd tiwmor â'r rhwystr gwaed-ymennydd. Mae'r gwaith hwn yn archwilio strategaethau therapiwtig newydd ac ailddefnyddio therapïau presennol i atal neu leihau lledaeniad metastatig.
2020-2026 Arweinydd Tîm ac Uwch Ddarlithydd: Canolbwyntiodd ymchwil ar rôl Cyffyrdd Tynn mewn dilyniant canser a'u modiwleiddio mewn clefyd anfalaen a patholegol, yn enwedig clefyd metastatig yr ymennydd. Fe wnes i hefyd ymchwilio i ffactorau angiogenig a'u rôl mewn metastasis. Fe wnes i oruchwylio nifer o PhD, MD, a chymrodyr ymchwil gwadd, cyflwyno dros 70 o bapurau mewn cynadleddau cenedlaethol a rhyngwladol, ac awdur erthyglau ymchwil gwreiddiol, adolygiadau gwahoddedig, a phenodau llyfrau. Fel gwyddonydd ymchwil, gweithiais ar ddau brosiect mawr, gan gynnwys astudiaeth a ariennir gan Abbott Pharmaceuticals (2003-2005) sy'n archwilio ffactorau sy'n effeithio ar athreiddedd cellog mewn canser y fron anfalaen a malaen, gyda ffocws penodol ar reoleiddio Cyffordd Dynn.
2003 - 2020 Darlithydd: Datblygu gwaith ymchwil ar Tight Junctions mewn cacner a chlefyd metastatig. Rhwng 2006-2011 cefais fy nghyflogi fel gwyddonydd ymchwil ar grant rhaglen a noddir gan Ymchwil Canser Cymru. Roedd hyn yn cynnwys archwilio Ffactor Twf Hepatocyte (HGF) a sut mae'r cytocin hwn yn dylanwadu ar farcwyr bôn-gelloedd mewn canser y fron a'r prostad (a ariennir gan Ymchwil Canser Cymru). Arweiniodd y gwaith hwn at ddyfarnu Ysgoloriaeth AACR-CTR-SABSC-Susan G, Komen ar gyfer "Gwerthuso dosbarthiad marcwyr bôn-gelloedd (PSCA, CD44, CD49b a CD133) mewn canser y fron dynol yn datgelu cydberthynas â dilyniant clinigol a chlefyd metastatig mewn carcinoma ductal".
Mawrth 2000 - Gorffennaf 2003 Cymrawd Ymchwil: Ymgymerodd â rhaglen ymchwil i bennu, gan ddefnyddio technegau moleciwlaidd, cellog ac in vivo, mecanweithiau metastasis canser yn enwedig cymhwyso posibl gwrthwynebwyr newydd i ffactorau twf fel offeryn gwrth-metastasis (Susan G. Komen Breast Cancer Foundation for a study on 'NK4, a HGF/SF antagonist, as a new anti-metastatic-agent in breast cancer). Dilynwyd hyn gan brosiect a noddwyd gan CR-UK a oedd yn cynnwys creu cyfansoddyn gwrth-metastasis/angiogenesis. Dechreuais hefyd ymchwilio i'r rôl y gall Cyffyrdd Tynn a'u cyfansoddion moleciwlaidd ei gael mewn metastasis canser y fron. Cydnabuwyd yr ymchwil hon yn Symposiwm Canser y Fron San Antonio 2002, lle cefais fy anrhydeddu â Gwobrau Ysgolhaig Astra-Zeneca sy'n dangos bod moleciwlau cyffordd dynn yn cael eu colli yn y cleifion hynny â chanser y fron metastatig.
Mehefin 1997- Mawrth 2000 Cymrawd Ymchwil: Sefydlu rôl ffibroblastau yn y broses o atgyweirio meinwe a metastasis canser, gan nodi ffactorau sy'n deillio o ffibroblastau sy'n gyfrifol am effaith reoleiddiol ffibroblastau, wrth hyrwyddo angiogenesis, yn yr Uned Ymchwil Iachau Clwyfau, Adran Llawfeddygaeth y Brifysgol yn y Drindod Dewi Sant, Caerdydd, y DU ar gyfer yr Athro K.G. Harding (a ariennir gan Smith & Nephew/Advanced Tissue Science Joint Venture).
Addysg a chymwysterau
- 2020: Rheolwr iACT
- 2013: Arweinyddiaeth a Rheolaeth y Brifysgol (ILM).
- 1996: PhD: Y Defnydd o RNA ribosomaidd 16S i ymchwilio i amrywiaeth ficrobaidd afon Epilithon yn yr Adran Bioleg Bur a Chymhwysol Coleg Prifysgol Cymru, Caerdydd.
- 1992: BSc (anrh) Microbioleg a Geneteg, Adran Bioleg Bur a Chymhwysol Coleg Prifysgol Cymru, Caerdydd. Prosiect Ymchwil Anrhydedd: Effaith Metel Gwenwynig a Ffactorau Allanol Eraill ar Dwf y Ffyngau Basidiomycete Hypholoma fasciculare.
Anrhydeddau a dyfarniadau
Penodiad fel Athro Gwadd yn Ysbyty Undeb Tsieina-Japan Prifysgol Jilin, 2-26-2027.
Penodiad fel Arbenigwr Rhyngwladol mewn Addysg Feddygol Ôl-raddedig yn Ysbyty Undeb Tsieina-Japan Prifysgol Jilin, 2025.
Gwobr Teithio BACR i'r 7fed Gynhadledd Tsieineaidd ar Oncoleg (CCO) a'r 11eg Gynhadledd Academaidd Traws-Culfor ar Oncoleg a Symposiwm Canser Gastro-berfeddol Tsieina-DU-Japan, 2012.
Gwobr Hyfforddiant Ysgolhaig AACR, a ariennir gan Susan G. Komen ar gyfer y Cure yn Symposiwm Canser y Fron CTRC-AACR San Antonio, Texas, Rhagfyr 2009 ar gyfer "Gwerthuso dosbarthiad marcwyr bôn-gelloedd mewn canser y fron dynol yn datgelu cydberthynas â dilyniant clinigol a chlefyd metastatig mewn carcinoma ductal".
Wrolegwyr Cymru Mawrth 2006 Asware N., Martin T.A., Matthews P.N., Jiang W.G. Wrolegwyr Cymru Mawrth 2003 Brown G.M., Martin T.A., Matthews P.N., Jiang W.G. "Mynegiant moleciwlau cyffordd dynn mewn canser y bledren ddynol"
Symposiwm Canser y Fron San Antonio, Rhagfyr 2004 Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG. "ROCK1 a natur ymosodol celloedd canser y fron".
Wrolegwyr Cymru Mawrth 2003 Brown G.M., Martin T.A., Matthews P.N., Jiang W.G. "Mynegiant moleciwlau cyffordd dynn mewn canser y bledren ddynol"
Ysgolhaig Astra-Zeneca yn Symposiwm Canser y Fron San Antonio, Rhagfyr 2002 ar gyfer "Mynegiant a dosbarthiad moleciwlau cyffordd dynn mewn canser y fron a'u cysylltiad â chanlyniadau clinigol" a gwahoddwyd i roi cyflwyniad llafar.
Ysgoloriaeth AACR Ebrill 2002 Davies G, Martin TA, Parr C, Grimshaw D, Mason MD, Jiang WG. "Lleihaodd NK4 dwf canser y prostad in vivo".
Tystysgrif Teilyngdod yng Nghynhadledd Cymdeithas Adfywio Meinwe America, Ebrill 2001 ar gyfer Martin TA, Jiang WG, a Harding KG. Effaith dermis sy'n deillio o ffibroblast dynol ar ehangu meinwe dynol. Cynhadledd Cymdeithas Adfywio Meinwe America.
Aelodaethau proffesiynol
- American Association of Cancer Research (AACR)
- Women in Cancer Research (WICR)
- British Association of Cancer Research
- European Association of Cancer Research
Safleoedd academaidd blaenorol
2026-Darllenydd cyfredol mewn Bioleg Celloedd a Chanser
2020-2026 - Uwch Ddarlithydd mewn Bioleg Celloedd a Chanser
2014-presennol – Arweinydd Grŵp, Cydweithredol Ymchwil Feddygol Caerdydd-Tsieina
2003 i 2014 – Darlithydd, Grŵp Ymchwil Metastasis ac Angiogenesis, Prifysgol Caerdydd
2000-2003 Cymrawd Ymchwil, Grŵp Ymchwil Metastasis ac Angiogenesis, Prifysgol Caerdydd
1997- 2000 Cymrawd Ymchwil, Uned Ymchwil Iachau Clwyfau, Adran Llawfeddygaeth y Brifysgol yng Ngholeg Meddygaeth Prifysgol Cymru
1996 Cynorthwy-ydd Ymchwil, Prifysgol Cymru Caerdydd
Pwyllgorau ac adolygu
2025-cyfredol Adolygydd Biobanc Prifysgol Caerdydd
2022-cyfredol Adolygydd Siarter Cydraddoldeb Hiliol AU Uwch
2016-cyfredol Pwyllgor EDI yr Ysgol Meddygaeth
2004-2024 HTRGC
2015-2020 Tîm Iechyd a Diogelwch DCAGE
2017-presennol Pwyllgor EDI DCG
Meysydd goruchwyliaeth
Goruchwyliaeth ymchwil ôl-raddedig amlddisgyblaethol: PhD a MD
Myfyriwr/myfyrwyr presennol:
- Qirui Tan PhD (cydweithrediad â Pheirianneg, yr Athro Johannes Benedikt)
Prosiectau Ffarmacoleg, MSc a Rhyngweithiol diweddar (2024):
Cymrodyr Ymchwil Rhyngwladol Diweddar:
Goruchwyliaeth gyfredol
Prosiectau'r gorffennol
Goruchwyliaeth lwyddiannus o dros 69 o brosiectau PhD, MPhil a MD.
Cwblhau diweddar:
2026: Yufei Lou
2025: Amber Li, Rhiannon Yu
2024: Henson Gao
Ymgysylltu
ArrayContact Details
[email protected]
+44 29206 87209
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Neuadd Meirionnydd, Llawr 4, Ystafell Swyddfa Ymchwil Ôl-raddedig, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS
+44 29206 87209
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Neuadd Meirionnydd, Llawr 4, Ystafell Swyddfa Ymchwil Ôl-raddedig, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS
Themâu ymchwil
Arbenigeddau
- Sgrinio canser, atal a diagnosis cynnar
- Bioleg celloedd canser
- Clefyd metastatig
- Triniaethau canser newydd